Pharma Corina Croitoru of Gedeon Richter Slovakia discusses GR’s footprint in the country, the affiliate’s main growth drivers, the importance of women’s health, and the intricacies of market access. Gedeon Richter’s affiliate in Slovakia was established back in 1996 and you yourself have been country manager for the past couple of…
Pharma MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth. The headline-making news at the moment is…
Ireland Dr. Paul Downing, General Manager of Hovione’s manufacturing plant in Cork, outlines the successes of the past few years, his emphasis on staff development and training, the CDMO’s advantages of agility and responsiveness, Ireland’s value proposition for the pharma manufacturing industry, and his vision for the next few years. Can…
Ireland Noel Heaney, general manager of BMS Biologics Ireland, provides an overview of BMS in Ireland, its exciting new USD 900 million biologics facility in Cruiserath, their innovative HR programs and his five-year-vision for BMS Biologics in Ireland. BMS has a strong heritage in Ireland dating back to 1964 when it…
Philippines Beaver Tamesis, Managing Director at MSD Philippines, discusses the company’s impressive growth in recent years as well as their expanding portfolio. Additionally, he discusses his work to foster engagement and motivation throughout the MSD affiliate in the country. When we first met you in 2013 you were only a few…
Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…
Ireland Julie O’Neill, Alexion’s EVP for Global Operations highlights Alexion’s establishment of its Global Supply Chain headquarters in Dublin, Ireland, its investment in Athlone, her thoughts on the opportunities and challenges in the Irish pharmaceutical landscape, and her vision for Alexion. Alexion first established a manufacturing presence in Dublin, Ireland in…
Pharma Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and the development path he will follow in order to foster growth. You took over the helm of the Mexican affiliate of…
Pharma Ireland is home to Recordati’s external supply operations and global in-licensing teams, alongside the API facility for one of the company’s most prolific products; Director Michael Kilkelly discusses the advantages of running such operations in Ireland, beyond the many financial incentives. In your opinion, why is Ireland such an attractive…
Pharma Efrén Ocampo, CEO of the Mexican pharmaceutical group Neolpharma, details the strategic thinking that has fostered the emergence of one of the most prominent healthcare groups in Mexico and the challenges and opportunities that lie ahead in Mexico and abroad. Neolpharma Group encompasses five manufacturing companies and 14 other service…
Ireland Barry Heavey, Head of Life Sciences at IDA Ireland, Ireland’s inward investment promotion agency, discusses IDA’s focus on acting as a catalyst for B2B collaboration in converging industries like connective health solutions and innovative drug delivery devices, their focus on advanced manufacturing, and his mission to make IDA Ireland the…
Pharma Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful of individuals in 2006 to 700 in Switzerland and 2,300 across Europe today; and how Celgene’s continuous R&D investment distinguishes…
See our Cookie Privacy Policy Here
